Decoding the Science of Life
The FDA has expanded the accelerated approval of sevabertinib, marketed as Hyrnuo, for adults with…
BridgeBio has reported new exploratory analyses from PROPEL 3, its Phase 3 study of oral…
Leyden Laboratories has reported positive Phase 1 findings for RIG-101, an investigational intranasal innate-immune modulator…
The FDA has expanded the accelerated approval of sevabertinib, marketed as Hyrnuo, for adults with locally advanced or metastatic non-squamous…
BridgeBio has reported new exploratory analyses from PROPEL 3, its Phase 3 study of oral infigratinib in children with achondroplasia.…
Leyden Laboratories has reported positive Phase 1 findings for RIG-101, an investigational intranasal innate-immune modulator intended to strengthen antiviral defenses…
Insilico Medicine has published an analysis of its Phase IIa idiopathic pulmonary fibrosis, or IPF, data in which six proteomic…
Clover Biopharmaceuticals has reported preliminary Phase 2 data for two respiratory combination-vaccine candidates aimed at older adults: SCB-1022, targeting RSV…
The U.S. Food and Drug Administration has approved Zanvastro, or zilganersen, for pediatric and adult patients with Alexander disease. The…
Ultragenyx has reported that its Phase 3 Aspire study of apazunersen, also called GTX-102, in Angelman syndrome did not meet…
THX Pharma, the Beyond Batten Disease Foundation and Biocodex have submitted regulatory applications to begin Batten-1-02, a Phase 3 study…
BioVie has completed the last on-treatment visit in its ADDRESS-LC Phase 2 study of bezisterim for neurological symptoms associated with…
Pfizer and BioNTech say FDA has approved the supplemental biologics license application for a 2026–27 COMIRNATY formulation targeting the XFG…
FDA has approved Lisraya, or brepocitinib, tablets for adults with dermatomyositis, creating the first FDA-approved oral treatment option for this…
